Primary pulmonary hypertension

Progress in Cardiovascular Diseases

Volumn 31, Issue 3, 1988, Pages 205-238

  Rich, Stuart ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMRINONE; ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; CAPTOPRIL; DIAZOXIDE; DIGOXIN; DILTIAZEM; DIURETIC AGENT; HYDRALAZINE; ISOPRENALINE; MINOXIDIL; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PRAZOSIN; TOLAZOLINE; VASODILATOR AGENT;

HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW;

DIGOXIN; DIURETICS; HUMANS; HYPERTENSION, PULMONARY; VASODILATOR AGENTS;

EID: 0024217417     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/0033-0620(88)90016-3     Document Type: Article

References (281)

1. Uver sklerose der lungenarterien
2. Ube die genuine arteriosklerose der lungenarterie
3. Obliterative pulmonary arteriosclerosis
4. Pathology of the vessels of the pulmonary circulation
5. Primary pulmonary hypertension 1. Clinical and hemodynamic study
6. Pulmonary hypertension with special reference to the vaso constrictive factor
7. Primary pulmonary hypertension A pathologic study of the lung vessels in 156 clinically diagnosed cases
8. Aminorex and pulmonary hypertension
9. Primary pulmonary hypertension: A national prospective study
10. Primary pulmonary arterial disease. Observations with special reference to medical thickening of small arteries and arterioles
11. Primary pulmonary hypertension, with special reference to prognosis
12. Primary pulmonary hypertension
13. Primary pulmonary hypertension
14. Pulmonary hypertension, eosinophila and filariasis
15. Primary pulmonary hypertension in India
16. Familial primary pulmonary hypertension: Clinical patterns
17. Familial pulmonary hypertension: Evidence of autosomal dominant inheritance
18. Primary pulmonary hypertension in childhood: A report of two brothers
19. Altitude and the human pulmonary circulation
20. Physiologic studies of pulmonary edema at high altitude
21. Pressure, flow and volume change of the lesser circulation during pulmonary artery occlusion in healthy subjects and patients with pulmonary hypertension
22. Pulmonary hypertension in isolated secundum atrial septal defect: High frequency in young patients
23. Small ventricular septal defect associated with severe pulmonary hypertension
24. Pulmonary vascular disease in secundum atrial septal defect with pulmonary hypertension
25. The early course of pulmonary artery hypertension in patients undergoing mitral valve replacement with cardioplegic arrest
26. Pulmonary hypertension: Individual and species variability relative to vascular reactivity
27. Plexogenic pulmonary hypertension of unknown origin. What's new?
28. Hypertensive pulmonary vascular disease. The point of no return
29. Pulmonary vascular disease with congenital heart lesions: Pathologic features and causes
30. Pulmonary vascular plexiform lesion
31. The pathologic physiology of microscopic pulmonary vascular shunts
32. Structure and significance of pulmonary plexiform structures
33. Primary pulmonary hypertension: A histopathologic study of 80 cases
34. Plexogenic pulmonary arteriopathy. Significance of medical thickness with respect to advanced pulmonary vascular lesions
35. Comparison of primary plexogenic arteriopathy in adults and children. A morphometric study in 40 patients
36. Lung biopsy specimens in the evaluation of pulmonary vascular disease
37. Primary pulmonary hypertension: Radiographic and scintigraphic patterns of histologic subtypes
38. Primary pulmonary hypertension and cirrhosis: Are they related?
39. Primary pulmonary hypertension: An unusual case associated with extrahepatic portal hypertension
40. Primary pulmonary hypertension after portacaval shunt
41. Prostaglandin action on the main pulmonary artery and portal vein of the rabbit
42. Raynaud's disease in primary pulmonary hypertension
43. Raynaud's disease and primary pulmonary hypertension
44. Thomboxane synthetase inhibition in primary pulmonary hypertension
45. The endothelial surface and responses to injury
46. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension
47. Von Willebrand factor abnormalities in primary pulmonary hypertension
48. Prostaglandin and hematologic characteristics of patients with primary pulmonary hypertension
49. Abnormal fibrinolysis in primary pulmonary hypertension
50. Pulmonary hypertension from chronic pulmonary thromboembolism
51. Evidence for increased thrombin activity in patients with primary pulmonary hypertension
52. Blood clotting studies in parturient women and the newborn
53. Clotting factors in pregnancy
54. Primary pulmonary hypertension: Natural history and the importance of thrombosis
55. A study of 43 cases of pulmonary veno-occlusive disease
56. Pulmonary veno-occlusive disease
57. Pulmonary veno-occlusive disease: A case report
58. Radiographic and angiographic characteristics of pulmonary veno-occlusive disease
59. Pulmonary veno-occlusive disease: Antemortem diagnosis from roentgenographic and hemodynamic findings
60. Pulmonary veno-occlusive disease: Involvement of the pulmonary arteries and review of the literature
61. Pulmonary vascular occlusion and fibrosing mediastinitis
62. Sclerosing mediastinitis with occlusion of pulmonary veins
63. Five cases of an undescribed form of pulmonary interstitial fibrosis caused by obstruction of the pulmonary veins
64. Pulmonary veno-occlusive disease Morphological changes suggesting a viral cause
65. Pulmonary veno-occlusive disease after chemotherapy
66. A case of pulmonary veno-occlusive disease Etiological and therapeutic appraisal
67. Case Records of the Massachusetts General Hospital (Case 14-1983)
68. Case Records of the Massachusetts General Hospital (Case 21-1986)
69. Familial pulmonary veno-occlusive disease: A case report
70. Pulmonary veno-occlusive disease in siblings: Case reports and morphometric study
71. Systemic lupus erythematosus and pulmonary vascular hypertension
72. Vascular lesions in systemic lupus erythematosus (SLE) with pulmonary hypertension
73. The pulmonary manifestations of systemic lupus erythematosus
74. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease
75. Cardiovascular manifestations of mixed connective tissue disease in adults
76. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis
77. Pulmonary hypertension in polymyositis
78. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma)
79. A study of etiologic factors in so-called primary pulmonary hypertension
80. Antinuclear antibodies in primary pulmonary hypertension
81. Primary pulmonary hypertension. An analysis of 28 cases and a review of the literature
82. Comparison of progressive exercise performance of normal subjects and patients with primary hypertension
83. The pathophysiology of failure in acute right ventricular hypertension: Hemodynamic and biochemical correlations
84. Recurrenslahmung bei mitral stenose
85. Ortner's syndrome associated with pulmonary hypertension
86. Left recurrent laryngeal nerve palsy associated with primary pulmonary hypertension and patent ductus arteriosus
87. The radiographic appearances in primary and thromboembolic pulmonary hypertension
88. Normal chest roentgenograms in chronic diffuse infiltrative lung disease
89. Electrocardiogram in primary pulmonary hypertension
90. Multifocal atrial tachycardia. Clinical and electrocardiographic features in 32 patients
91. Restrictive ventilatory pattern in precapillary pulmonary hypertension
92. Mechanisms of gas exchange abnormality in patients with chronic obliterative pulmonary vascular disease
93. Cardiopulmonary function in patients with pulmonary hypertension
94. Perfusion lung scanning in obliterative pulmonary hypertension
95. Chronic thrombotic obstruction of major pulmonary arteries: Results of thromboendarterectomy in 15 patients
96. Perfusion lung scans vs pulmonary angiography in the evaluation of suspected primary pulmonary hypertension
97. Modifications of techniques and early results of pulmonary thromboendarterectomy for chronic pulmonary embolism
98. Fatality immediately following rapid infusion of macroaggregates of 99-Tc albumen (MAA) for lung scan
99. Death following injection of lung scanning agent in a case of pulmonary hypertension
100. Fatal lung scan in a case of pulmonary hypertension due to obliterative pulmonary vascular disease
101. Automated morphologic evaluation of pulmonary arteries in primary pulmonary hypertension
102. Magnification pulmonary wedge angiography in the evaluation of children with congenital heart disease and pulmonary hypertension
103. Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects
104. Arteriographic assessment of lung scanning in the diagnosis of pulmonary thromboembolism
105. The incidence, etiologies, and avoidance of complications of pulmonary angiography in a large series
106. The complementary roles of chest radiography, lung scanning, and selective pulmonary angiography in the diagnosis of pulmonary embolism
107. The lungs as receptor sites for cardiovascular regulation
108. Pulmonary arteriography in the high-risk patient
109. Echocardiographic features of primary pulmonary hypertension
110. Echocardiographic patterns of pulmonic valve motion with pulmonary hypertension
111. Contrast echocardiography in pulmonary hypertension: Observations explaining early closure of the pulmonic valve
112. Noninvasive assessment of right ventricular systolic pressure in atrial septal defect: Analysis of the end-systolic configuration of the ventricular septum by two-dimensional echocardiography
113. The effects of pressure-induced right ventricular hypertrophy on left ventricular diastolic properties and dynamic geometry in the conscious dog
114. Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: A cross-sectional echocardiographic study
115. Doppler echocardiographic assessment of impaired left ventricular filling in patients with right ventricular pressure overload due to primary pulmonary hypertension
116. A reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: Guidelines for determining a pulmonary vasodilator response
117. Deleterious effects of hydralazine in patients with primary pulmonary hypertension
118. Noninvasive evaluation of pulmonary hypertension by a pulsed Doppler technique
119. Doppler echocardiographic prediction of pulmonary arterial hypertension in congenital heart disease
120. Comparison of Doppler-determined elevated pulmonary arterial pressure with pressure measured at cardiac catheterization
121. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound
122. Continuous-wave Doppler echocardiographic detection of pulmonary regurgitation and its application to noninvasive estimation of pulmonary artery pressure
123. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography
124. Use of continuous-wave Doppler ultrasound to evaluate and manage primary pulmonary hypertension
125. Left atrial-pulmonary artery wedge pressure relation: Effect of elevated pulmonary vascular resistance
126. Factors that influence the outcome of primary pulmonary hypertension
127. Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension
128. Pulmonary hemodynamics in primary pulmonary hypertension
129. Multicenter trial of a new guidewire thermodilution catheter
130. Physiologic correlates of right ventricular ejection fraction in COPD: A combined radionuclide and hemodynamic study
131. Equilibrium radionuclide right ventriculography at rest and during exercise in patients with pulmonary hypertension
132. Hemodynamic correlates of right ventricular ejection fraction measured with gated radionuclide angiocardiography
133. Improved radionuclide method for assessment of pulmonary artery pressure in COPD
134. CT-determined pulmonary artery diameters in predicting pulmonary hypertension
135. The normal roentgenographic measurement of the right descending pulmonary artery in 1085 cases
136. Pulmonary artery hypertension in chronic obstructive lung disease Determination by chest radiography
137. CT findings in pulmonary venooclusive disease
138. Magnetic resonance imaging in pulmonary arterial hypertension
139. Pathologic blood flow in pulmonary vascular disease as shown by gated magnetic resonance imaging
140. Primary pulmonary hypertension
141. Primary pulmonary hypertension of unusually long duration
142. Long-term followup in primary pulmonary hypertension
143. Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation
144. Pulmonary vascular response is dependent upon initial state of the vasculature
145. Comparison of mechanical and chemical properties of extra- and intralobar canine pulmonary arteries
146. An unusual case of rapidly progressive primary pulmonary hypertension childhood
147. Regression of primary pulmonary hypertension
148. A case of spontaneous resolution of idiopathic pulmonary hypertension
149. Right ventricular function in acute disease states: Pathophysiologic considerations
150. Sudden unexpected death from primary pulmonary hypertension
151. On the cause of syncope and sudden death in primary pulmonary hypertension
152. The pressure-flow response of the pulmonary circulation in patients with heart failure and pulmonary vascular disease
153. Primary pulmonary hypertension in pregnancy
154. Peripartum heart failure due to primary pulmonary hypertension
155. Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy
156. Digoxin prophylaxis for prevention of the cardiac contractile defect produced by pressure overload
157. Chronic cor pulmonale
158. Pulmonary vascular resistance. A meaningless variable
159. Unilateral pulmonary artery occlusion in man. Control studies
160. The relation between pressure and flow in the pulmonary circulation in normal subjects and patients with chronic bronchitis and mitral stenosis
161. Unilateral pulmonary artery occlusion in man. II. Studies in patients with chronic pulmonary disease
162. On pulmonary vascular resistance: The need for a more precise definition
163. Magnitude and implications of spontaneous hemodynamic variability in primary pulmonary hypertension
164. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency
165. Antiarrhythmic drug effect mimicked by spontaneous variability of ventricular ectopy
166. Arterial blood pressure measurements with a portable recorder in hypertension patients. I. Variability and correlations with “casual” pressures
167. Captopril as treatment for patients with pulmonary hypertension. Problems of variability in assessing chronic drug treatment
168. The case for treatment of selected patients with primary pulmonary hypertension
169. Pulmonary vascular tone improves VA/Q matching in obliterative pulmonary hypertension
170. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease
171. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease
172. Effects of nifedipine on ventilation/perfusion matching in primary pulmonary hypertension
173. Recent studies in primary pulmonary hypertension including pharmacodynamic observation on pulmonary vascular resistance
174. Primary pulmonary hypertension in a child. Response to pharmacologic agents
175. Tolazoline hydrochloride (priscoline): An effective pulmonary vasodilator
176. Effects of tolazoline hydrochloride (priscoline) on circulatory dynamics in patients with pulmonary hypertension
177. The use of tolazoline hydrochloride as a pulmonary vasodilator in potentially fatal episodes of pulmonary vasoconstriction after cardiac surgery in children
178. Intracardiac infusion of acetylcholine in primary pulmonary hypertension
179. Primary pulmonary hypertension Effect of unilateral pulmonary artery occlusion and infusion of acetylcholine
180. Effect of acetylcholine on pulmonary vascular resistance in a patient with idiopathic pulmonary hypertension
181. Loss of reactivity of the pulmonary vascular bed in primary pulmonary hypertension
182. The hemodynamic effects of isoproterenol on pulmonary hypertension in man
183. Primary pulmonary hypertension: Favorable effect of isoproterenol
184. Sustained improvement in primary pulmonary hypertension during six years of treatment with sublingual isoproterenol
185. Unfavorable hemodynamic and clinical effects of isoproterenol in primary pulmonary hypertension
186. Isoproterenol as a potential pulmonary vasodilator in primary pulmonary hypertension
187. Primary pulmonary hypertension: Responses to indomethacin, terbutaline and isoproterenol
188. Effect of sympathetic nerve stimulation on pulmonary vascular resistance in the dog
189. Mechanisms underlying vasomotor regulation of regional pulmonary blood flow in normal and disease states
190. Autonomic vasomotor tone in the pulmonary circulation
191. Primary pulmonary hypertension treated with oral phentolamine
192. Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension
193. Beneficial effects of phentolamine and nifedipine in primary pulmonary hypertension
194. Treatment of primary pulmonary hypertension by alpha blockade
195. Diazoxide in the treatment of primary pulmonary hypertension
196. Remission of primary pulmonary hypertension during treatment with diazoxide
197. Diazoxide in primary pulmonary hypertension
198. Clinical and hemodynamic effects of diazoxide in primary pulmonary hypertension
199. Comparative hemodynamic and clinical responses to isuprel, diazoxide and hydralazine in severe precapillary pulmonary hypertension
200. Diazoxide in the treatment of primary pulmonary hypertension
201. Hazards of diazoxide in pulmonary hypertension
202. Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension
203. Vasodilator therapy in primary pulmonary hypertension
204. Reversibility of primary pulmonary hypertension during six years of treatment with oral diazoxide
205. Afterload reduction and cardiac output in infants early after intracardiac surgery
206. Acute hemodynamic effects of nitroglycerin in pulmonary hypertension
207. Oral hydralazine therapy for primary pulmonary hypertension
208. The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause
209. Comparative effects of hydralazine, nifedipine, and amrinone in primary pulmonary hypertension
210. Hemodynamic response to intravenous hydralazine in patients with pulmonary hypertension
211. Adverse effect of hydralazine in patients with primary pulmonary hypertension
212. Mechanism of action of calcium channel blocking agents
213. Comparative effects of nifedipine, verapamil, and diltiazem on experimental pulmonary hypertension
214. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs
215. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine
216. Primary pulmonary hypertension improved by long-term oral administration of nifedipine
217. Nifedipine in the treatment of primary pulmonary hypertension
218. Hemodynamic effects of nifedipine in primary pulmonary hypertension
219. Sustained beneficial effect of nifedipine in primary pulmonary hypertension
220. Primary pulmonary hypertension: Effects of nifedipine
221. Treatment of primary pulmonary hypertension with nifedipine: A hemodynamic and scintigraphic evaluation
222. Hemodynamic effects of nifedipine at rest and during exercise in primary pulmonary hypertension
223. Hemodynamic effects of nifedipine and hydralazine in primary pulmonary hypertension
224. Primary pulmonary hypertension: Effects of nifedipine
225. Hypotension and sinus arrest with nifedipine in pulmonary hypertension
226. Pulmonary edema with nifedipine in primary pulmonary hypertension
227. Primary pulmonary hypertension nifedipine and hypoxemia
228. Failure of nifedipine treatment in primary pulmonary hypertension
229. Fatal outcome following nifedipine for primary pulmonary hypertension
230. Rapid attenuation of response to nifedipine in primary pulmonary hypertension
231. Verapamil and pulmonary hypertension
232. Primary pulmonary hypertension: Beneficial therapy with diltiazem
233. Hemodynamic and gas exchange effects of intravenous diltiazem in patients with pulmonary hypertension
234. Verapamil in primary pulmonary hypertension
235. Comparison of prostacyclin to acute and chronic diltiazem in primary pulmonary hypertension
236. Hypoxic pulmonary vasoconstriction in the rat. The necessary role of angiotension II
237. Hydrolysis of bradykinin and its higher homologues by angiotension converting enzymes
238. Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat
239. Effects of captopril (sq 14,225) in a patient with primary pulmonary hypertension
240. Hemodynamic and hormonal effects of captopril in primary pulmonary hypertension
241. Is captopril effective in primary pulmonary hypertension?
242. Captopril versus hydralazine in primary pulmonary hypertension
243. Captopril in primary pulmonary hypertension
244. Persistent hemodynamic and clinical improvement after captopril in patients with pulmonary hypertension
245. Precapillary pulmonary hypertension: Effect of captopril
246. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure
247. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension
248. Regression in thromboembolic type of primary pulmonary hypertension during 2-1/2 years of antithrombotic therapy
249. Rat pulmonary circulation after chronic hypoxia: Hemodynamics and structural features
250. Reversal of pulmonary hypertension by prolonged oxygen administration to patients with chronic bronchitis
251. Effect of oxygen on pulmonary vascular resistance in patients with pulmonary hypertension associated with atrial septal defect
252. Long-term favorable effect of oxygen administration on a patient with primary pulmonary hypertension
253. Systemic vasoconstrictor effects of oxygen administration in obliterative pulmonary vascular disorders
254. + ion concentration changes
255. 2 in intact-chest cats
256. Effect of amrinone on right ventricular function: Predominance of afterload reduction
257. Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure
258. Treatment of right ventricular dysfunction in acute respiratory failure
259. Acute circulatory effects of dopamine in patients with pulmonary hypertension
260. Effects of nitroprusside and dopamine on the pulmonary arterial vasculature in children after cardiac surgery
261. Volume versus dopamine to maintain cardiac output as right ventricular afterload increases
262. High dose calcium blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
263. Prostaglandins and the lungs
264. The role of endogenous prostaglandins in the pulmonary circulation
265. Pulmonary alveolar hypoxia: release of prostaglandins and other humoral mediators
266. 1 on the pulmonary circulation in patients with pulmonary hypertension
267. 1 for severe idiopathic pulmonary artery hypertension
268. Prostacyclin-induced pulmonary vasodilation in primary pulmonary hypertension
269. Comparable hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension
270. Hydralazine in pulmonary hypertension
271. Pharmacologically induced pulmonary vasodilation in children and young adults with primary pulmonary hypertension
272. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin)
273. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man
274. A potential new role for open lung biopsies in the evaluation of unexplained pulmonary hypertension
275. Fate of the patient with Eisenmerger syndrome
276. Experimental studies of the surgical treatment of primary pulmonary hypertension
277. Prevention of postoperative right ventricular failure by a prosthetic patent foramen ovale
278. Atrial septostomy as palliative therapy for refractory primary pulmonary hypertension
279. Heart-lung transplantation. Successful therapy for patients with pulmonary vascular disease
280. Long-term results, hemodynamics, and complications after combined heart and lung transplantation